The Technical Analyst
Lantern Pharma Inc. [LTRN]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Lantern Pharma Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
-6.76% $5.38
America/New_York / 24 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 57.79 mill |
| EPS: | -1.470 |
| P/E: | -3.66 |
| Earnings Date: | May 07, 2024 |
| SharesOutstanding: | 10.74 mill |
| Avg Daily Volume: | 0.319 mill |
| RATING 2024-04-24 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Sell | |
| P/E: | Sell | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -3.66 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.62x |
| Company: PE -3.66 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$2.00 (-62.79%) $-3.38 |
| Date: 2024-04-25 |
| Expected Trading Range (DAY) |
|---|
|
$ 4.14 - 6.62 ( +/- 22.99%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-02-27 | Fletcher Aaron G.l. | Sell | 34 731 | Common Stock |
| 2024-02-28 | Fletcher Aaron G.l. | Sell | 51 608 | Common Stock |
| 2024-02-29 | Fletcher Aaron G.l. | Sell | 13 686 | Common Stock |
| 2024-02-27 | Fletcher Aaron G.l. | Sell | 10 620 | Common Stock |
| 2024-02-28 | Fletcher Aaron G.l. | Sell | 15 780 | Common Stock |
| INSIDER POWER |
|---|
| -62.86 |
| Last 98 transactions |
| Buy: 4 152 509 | Sell: 1 662 260 |
Forecast:
16:00 - $5.39
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $5.39
Forecast 2: 16:00 - $5.39
Forecast 3: 16:00 - $5.39
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $5.38 (-6.76% ) |
| Volume | 0.0961 mill |
| Avg. Vol. | 0.319 mill |
| % of Avg. Vol | 30.15 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For LTRN
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
LTRN
Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer. The company also develops LP-300 as a combination therapy for non or never-smokers with non-small cell lung cancer adenocarcinoma. In addition, its preclinical development drug candidate is LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers or that harbor mutations in DNA repair pathways. Further, the company operates ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Additionally, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. The company was incorporated in 2013 and is headquartered in Dallas, Texas.
Latest Press Releases
2024-04-24 08:00:00 - Press Release
Lantern Pharma Launches “webinar Wednesdays” Featuring World-class Physician Scientists & Key Opinion Leaders Discussing Critical Areas Of Oncology Drug Development
Dallas--(business wire)--lantern pharma inc. (nasdaq: ltrn), an artificial intelligence (“ai”) company developing targeted and transformative cancer therapies using its proprietary radr® ai and machine learning (“ml”) platform with multiple clinical-stage drug programs, announced today that – the company has launched webinar wednesdays, a webinar series that focuses on areas of high oncology drug development interest with leading physicians, scientists and lantern collaborators in drug developm.
2024-04-22 08:12:00 - Press Release
Lantern Pharma Receives Regulatory Approval To Expand Harmonic™ Clinical Trial For Non-small Cell Lung Cancer In Never-smokers Into Japan And Taiwan
Dallas--(business wire)--lantern pharma inc. (nasdaq: ltrn), an artificial intelligence (“ai”) company developing targeted and transformative cancer therapies using its proprietary radr® ai and machine learning (“ml”) platform with multiple clinical-stage drug programs, announced today that – the company has received regulatory approval to expand its harmonic™ trial, a phase 2 clinical study evaluating lp-300 in non-small cell lung cancer (nsclc) in never-smokers in both japan and taiwan. appro.
2024-03-18 16:02:00 - Press Release
Lantern Pharma Reports Fourth Quarter & Fiscal Year 2023 Financial Results And Business Highlights
Dallas--(business wire)--lantern pharma inc. (nasdaq: ltrn), an artificial intelligence (“ai”) company developing targeted and transformative cancer therapies using its proprietary radr® ai and machine learning (“ml”) platform with multiple clinical-stage drug programs, today announced operational highlights and financial results for the fourth quarter and fiscal year ended december 31, 2023. “this past quarter and the entire year of 2023 was a period of meaningful and remarkable progress for o.
2024-03-15 08:00:00 - Press Release
Lantern Pharma Announces Initial Patients Dosed In First-in-human Clinical Trial For Ai-guided Drug-candidate, Lp-284
Dallas--(business wire)--lantern pharma inc. (nasdaq: ltrn), an artificial intelligence (ai) company developing targeted and transformative cancer therapies using its proprietary ai and machine learning (ml) platform, radr®, with multiple clinical stage drug programs, today announced the dosing of the first two patients in the phase 1 clinical trial evaluating lantern's investigational new drug lp-284 in patients with relapsed or refractory non-hodgkin's lymphoma (nhl), including mantle cell ly.
2024-03-11 07:30:00 - Press Release
Lantern Pharma To Report Fourth Quarter And Fiscal Year 2023 Operating & Financial Results On March 18th, 2024 At 4:30 P.m. Et
Dallas--(business wire)--lantern pharma inc. (nasdaq: ltrn), an artificial intelligence (“ai”) company developing targeted and transformative cancer therapies using its proprietary radr® ai and machine learning (“ml”) platform with multiple clinical stage drug programs, today announced that it will host its fourth quarter and fiscal year 2023 financial results webcast on monday, march 18, 4:30 p.m. eastern time / 1:30 p.m. pacific time. management intends to discuss the operating and financial.
Latest News
2024-03-18 23:14:02 - Seeking Alpha
Lantern Pharma Inc. (LTRN) Q4 2023 Earnings Call Transcript
2024-03-11 07:30:00 - Business Wire
Lantern Pharma to Report Fourth Quarter and Fiscal Year 2023 Operating & Financial Results on March 18th, 2024 at 4:30 p.m. ET
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning (“ML”) platform with multiple clinical stage drug programs, today announced that it will host its fourth quarter and fiscal year 2023 financial results webcast on Monday, March 18, 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time. Management intends to discuss the operating and financial.
2023-12-13 08:05:00 - InvestorPlace
The 3 Most Undervalued AI Penny Stocks to Buy in December
It's easy to understand why investors remain curious about AI penny stocks in December and beyond. Leading companies in the artificial intelligence (AI) industry have multiplied in value in 2023.
2023-11-09 05:28:04 - Seeking Alpha
Lantern Pharma Inc. (LTRN) Q3 2023 Earnings Call Transcript
Lantern Pharma Inc. (NASDAQ:LTRN ) Q3 2023 Earnings Conference Call November 8, 2023 4:30 PM ET Company Participants Panna Sharma - President and Chief Executive Officer David Margrave - Chief Financial Officer Conference Call Participants Operator Good afternoon, and welcome to our Third Quarter 2023 Earnings Call. As a reminder, this call is being recorded and all attendees are in a listen-only mode.
2023-09-14 09:09:31 - InvestorPlace
The 3 Most Undervalued Machine Learning Stocks to Buy in September 2023
If you're wondering if there is still time to invest in machine learning stocks, some recent research will provide some useful context. A recent study by WallStreetZen revealed what many investors already suspected.
2023-08-28 17:32:36 - InvestorPlace
3 AI Stocks That Still Trade Under $10 Per Share
The artificial intelligence ( AI ) boom is far from over. For example let's look at Nvidia (NASDAQ: NVDA ), where CEO Jensen Huang still believes his stock is wildly undervalued.
2023-08-23 18:00:58 - InvestorPlace
The 3 Most Undervalued Machine Learning Stocks to Buy Now: August 2023
Despite the pullback in the technology indices and that of the broader market, the transition to artificial intelligence ( AI ) has only just begun. ChatGPT kicked off this sudden surge of interest in machine learning stocks, and it looks to have a transformational impact on society.
2023-08-16 16:58:09 - InvestorPlace
The 3 Most Undervalued AI Penny Stocks to Buy Now: August 2023
If you've been on the sidelines with artificial intelligence stocks, the recent pullbacks are handing investors another opportunity to buy. That includes the likes of Nvidia (NASDAQ: NVDA ), Microsoft (NASDAQ: MSFT ), Advanced Micro Devices (NASDAQ: AMD ), Palantir (NYSE: PLTR ) and dozens more, even in AI penny stocks.
2023-08-09 20:25:25 - Seeking Alpha
Lantern Pharma Inc. (LTRN) Q2 2023 Earnings Call Transcript
Lantern Pharma Inc. (NASDAQ:LTRN ) Q2 2023 Earnings Conference Call August 9, 2023 4:30 PM ET Company Participants Nicole Leber – Investor Relations Panna Sharma – Chief Executive Officer David Margave – Chief Financial Officer Conference Call Participants Nicole Leber Good afternoon, everyone. I'm Nicole Leber with Investor Relations here at Lantern Pharma.
2023-08-09 09:11:07 - InvestorPlace
3 AI Penny Stocks With the Potential to Make Your Financial Dreams Come True
As we forge ahead into the AI era, the top AI penny stocks have become increasingly relevant, emerging as a buzzword among savvy investors. Projected to inject a massive $15.7 trillion into the global economy by the conclusion of the current decade, AI is no longer just the playground for large-cap tech giants.